Transgene Biotek has reported the resignation of its statutory auditor, M/s Eswara Rao & Co., effective October 28, 2026. The auditor, appointed earlier this month, cited a family medical emergency as the primary reason for leaving. Notably, the firm confirmed that no audit work had commenced, no management friction occurred, and no concerns were raised to the audit committee. The company must now move to appoint a successor to handle the pending financial review for the September quarter.
Transgene Biotek Auditor Resigns Prematurely
Auditor M/s Eswara Rao & Co. resigned effectively on October 28, 2026, after being appointed just eighteen days prior on October 10, 2026. The firm stated that unforeseen family medical emergencies prevented them from fulfilling their obligations.
Reader Takeaway: Auditor exited due to personal emergencies; confirmed no disagreements with management or pending audit concerns remain.
What just happened
Transgene Biotek informed the BSE that their recently appointed statutory auditor has stepped down. The auditor cited a need for both partners to travel unexpectedly for medical emergencies. The firm noted that, as first-year auditors, the time pressure to complete the September quarter's limited review would have compromised their ability to perform a high-quality audit under the current circumstances.
Why this matters
For retail investors, a change in auditor is often a red flag. However, the auditor explicitly clarified that they had not yet commenced any audit or limited review work. Furthermore, they confirmed that there was no non-cooperation from the company management and no unresolved concerns were presented to the audit committee.
Risks to watch
While the company has signaled no internal conflict, the primary risk for shareholders remains the delay in the financial review for the quarter ended September 30, 2026. The company must now act swiftly to appoint a replacement to ensure regulatory compliance and timely disclosure of quarterly financial results.
What to track next
Investors should monitor the next BSE filing regarding the appointment of a new auditor and any subsequent timelines provided by the company for the completion of the pending quarterly financial review.